157 related articles for article (PubMed ID: 37901123)
1. Efficacy and Safety of Cefmetazole for Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales vs Carbapenems: A Retrospective Study.
Kashihara E; Sada RM; Tsugihashi Y; Obayashi H; Nakamura A; Abe N; Miyake H; Akebo H
Open Forum Infect Dis; 2023 Oct; 10(10):ofad502. PubMed ID: 37901123
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of cefmetazole versus carbapenems and piperacillin/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study.
Aoto K; Inose R; Kosaka T; Shikata K; Muraki Y
J Infect Chemother; 2024 Mar; 30(3):213-218. PubMed ID: 37832824
[TBL] [Abstract][Full Text] [Related]
3. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
4. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales.
Iio K; Hagiya H; Higashionna T; Otsuka F
New Microbiol; 2024 Jan; 46(4):348-353. PubMed ID: 38252045
[TBL] [Abstract][Full Text] [Related]
5. Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing
Park JJ; Jung EJ; Kim JY; Seo YB; Lee J; Jung Y
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0028722. PubMed ID: 35708330
[TBL] [Abstract][Full Text] [Related]
6. Effect of Different Approaches to Antimicrobial Therapy with Cefmetazole and Meropenem on the Time to Defervescence in Non-Severe Extended-Spectrum β-Lactamase-Producing
Hoshi T; Fujii S; Watanabe K; Fukumura Y; Miyazaki K; Takahashi M; Taniguchi S; Kimura S; Saito A; Wada N; Saijo M; Yamada K; Iwayama K; Itaya M; Sato H
Infect Dis Rep; 2023 Dec; 16(1):26-34. PubMed ID: 38247975
[TBL] [Abstract][Full Text] [Related]
7. Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series.
Kuwana T; Yamaguchi J; Kinoshita K; Hori S; Ihara S; Taniguchi T
Open Med (Wars); 2020; 15(1):782-786. PubMed ID: 33336036
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of empiric carbapenem versus non-carbapenem therapy for extended-spectrum β-lactamase producing Enterobacterales infections in non-intensive care unit patients: a real-world investigation in a hospital with high-prevalence of extended-spectrum β-lactamase producing Enterobacterales.
Kang AY; Elkomos M; Pham D; Guerrero M; Kupferwasser D; Miller LG
Antimicrob Steward Healthc Epidemiol; 2024; 4(1):e100. PubMed ID: 38836043
[TBL] [Abstract][Full Text] [Related]
10. Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli.
Hamada Y; Matsumura Y; Nagashima M; Akazawa T; Doi Y; Hayakawa K
J Infect Chemother; 2021 Nov; 27(11):1602-1606. PubMed ID: 34348852
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics analysis and establishment of optimal dosing regimens using unbound cefmetazole concentration for patients infected with Extended-Spectrum β-lactamase producing Enterobacterales (ESBL-E).
Namiki T; Yokoyama Y; Hashi H; Oda R; Jibiki A; Kawazoe H; Matsumoto K; Suzuki S; Nakamura T
Pharmacotherapy; 2024 Feb; 44(2):149-162. PubMed ID: 37984818
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of surveillance cultures for bacteremia caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales among patients with hematological diseases.
Hattori T; Goto T; Osaki M; Ozawa Y; Miyamura K
Infection; 2022 Jun; 50(3):753-759. PubMed ID: 35013943
[TBL] [Abstract][Full Text] [Related]
15. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
Takemura W; Tashiro S; Hayashi M; Igarashi Y; Liu X; Mizukami Y; Kojima N; Morita T; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
Pharm Res; 2021 Nov; 38(11):1839-1846. PubMed ID: 34853981
[TBL] [Abstract][Full Text] [Related]
16. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
17. Cefmetazole Resistance Mechanism for
Ito R; Kawamura M; Sato T; Fujimura S
Infect Drug Resist; 2022; 15():5867-5878. PubMed ID: 36237294
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis.
Huang PY; Hsu CK; Liu TH; Wu JY; Tang HJ; Tsai YW; Lai CC; Chang YH
J Glob Antimicrob Resist; 2023 Jun; 33():201-207. PubMed ID: 36944409
[TBL] [Abstract][Full Text] [Related]
19. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
